Added to YB: 2026-02-03
Pitch date: 2026-02-01
TEVA [neutral]
Teva Pharmaceutical Industries Limited
+1.33%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Market Cap
$39.6B
Pitch Price
$105.00
Price Target
60.00 (-44%)
Dividend
N/A
EV/EBITDA
10.43
P/E
28.08
EV/Sales
3.09
Sector
Pharmaceuticals
Category
turnaround
Teva’s ($TEVA) Pivot to Growth hits high Gear: Q4 results and beyond
TEVA (update): Entered 'Acceleration Phase' - innovative brands AUSTEDO/AJOVY/UZEDY hit $1B+ Q4 rev milestone. FY25: $17.3B rev (+5%), $5.3B EBITDA (+12%), $2.93 EPS (+19%). Pipeline $10B+ peak sales potential. Despite $1.1B Revlimid headwind 2026, expects EBITDA growth. Price targets $28-40, author sees $58-60 in 24-36mo.
Read full article (3 min)